Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024

Rhea-AI Summary

Elutia Inc. (Nasdaq: ELUT) will showcase its CanGaroo® BioEnvelope product line at the Heart Rhythm Society's annual meeting. The innovative biologic matrix enhances device stability and patient comfort for cardiac implantable electronic devices. Elutia's management team will be present at the event to demonstrate the product's benefits.

Positive

• Elutia's participation in HRS 2024 allows for the showcasing of the CanGaroo® BioEnvelope product line.

• The biologic matrix of the envelope promotes a natural healing response and enhances device stability and patient comfort.

• The CanGaroo® BioEnvelope is clinically proven to reduce post-surgical device implantation complications, leading to improved patient outcomes.

Negative

• None.

SILVER SPRING, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, is excited to announce its participation in the upcoming Heart Rhythm Society's annual meeting (HRS 2024), where it will showcase its innovative CanGaroo^® BioEnvelope product line. Designed specifically for cardiac implantable electronic devices (CIEDs), the biologic matrix of the envelope works with the body to promote a natural healing response and enhance device stability and patient comfort. Join us at the Boston Convention & Exhibition Center from May 16-18, 2024, where Elutia will demonstrate the future of cardiac device protection at Booth #1443.

Elutia management attending HRS 2024 includes Dr. Randy Mills, Chief Executive Officer; Matt Ferguson, Chief Financial Officer; Dr. Michelle Williams, Chief Scientific Officer; and Dr. Kimberly Mulligan, Vice President and General Manager of Cardiovascular. Attendees interested in scheduling a meeting with management during the conference may register through the HRS 2024 meeting portal here or contact ir@elutia.com.

The CanGaroo BioEnvelope comprises an acellular biologic matrix that promotes a biologic healing response at the interface between the CIED and the patient. This enhances patient outcomes by minimizing inflammation and promoting the stimulation of healthy, vascularized tissue. Designed for use in patients with pacemakers and internal defibrillators, CanGaroo is clinically proven to reduce post-surgical device implantation complications.

About Elutia

Elutia develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com

 

FAQ

What is Elutia showcasing at Heart Rhythm 2024?

Elutia will showcase its CanGaroo® BioEnvelope product line at the event.

What is the purpose of the CanGaroo® BioEnvelope?

The biologic matrix of the CanGaroo® BioEnvelope enhances device stability and patient comfort for cardiac implantable electronic devices.

Who will be attending HRS 2024 from Elutia's management team?

Dr. Randy Mills, Matt Ferguson, Dr. Michelle Williams, and Dr. Kimberly Mulligan will be present at the event.

How can attendees schedule a meeting with Elutia's management during the conference?

Attendees can register through the HRS 2024 meeting portal or contact ir@elutia.com for scheduling a meeting with Elutia's management.

What are the benefits of using the CanGaroo® BioEnvelope?

The CanGaroo® BioEnvelope minimizes inflammation, promotes healthy tissue stimulation, and reduces post-surgical device implantation complications.